How much is CTI Biopharma worth?
One share of CTIC stock can currently be purchased for approximately $2.22. How much money does CTI BioPharma make? CTI BioPharma has a market capitalization of $214.66 million and generates $3.35 million in revenue each year.
Where can I buy shares of CTIC?
Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How far is CTI Biopharma from the 52-week low?
According to the current price, CTI BioPharma is 378.40% away from the 52-week low. What was the 52-week high for CTI BioPharma stock? The high in the last 52 weeks of CTI BioPharma stock was 5.76.
Is CTIC a good stock to buy?
Is Cti Biopharma Stock a good buy in 2022, according to Wall Street analysts? The consensus among 4 Wall Street analysts covering (NASDAQ: CTIC) stock is to Strong Buy CTIC stock.
Is CTI BioPharma a buy?
CTI BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Should I buy or sell CTI BioPharma stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 5 buy ratings for the...
What is CTI BioPharma's stock price forecast for 2022?
5 equities research analysts have issued 1 year price targets for CTI BioPharma's stock. Their forecasts range from $6.00 to $12.00. On average, th...
How has CTI BioPharma's stock performed in 2022?
CTI BioPharma's stock was trading at $2.48 at the start of the year. Since then, CTIC stock has increased by 139.9% and is now trading at $5.95. V...
Are investors shorting CTI BioPharma?
CTI BioPharma saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 13,020,000 shares, an increas...
When is CTI BioPharma's next earnings date?
CTI BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for CTI Bi...
How were CTI BioPharma's earnings last quarter?
CTI BioPharma Corp. (NASDAQ:CTIC) released its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.37) earnings per...
When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?
CTI BioPharma shares reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of s...
Who are CTI BioPharma's key executives?
CTI BioPharma's management team includes the following people: Dr. Adam R. Craig M.B.A. , M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer &...
What is James A. Bianco's approval rating as CTI BioPharma's CEO?
8 employees have rated CTI BioPharma CEO James A. Bianco on Glassdoor.com . James A. Bianco has an approval rating of 27% among CTI BioPharma's em...
How much does CTI Biopharma make?
When did the 1-10 split happen?
How much money does CTI BioPharma make? CTI BioPharma has a market capitalization of $225.74 million and generates $3.35 million in revenue each year. The biopharmaceutical company earns $-52,450,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.
What is CTI Biopharma?
The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.
Where is CTI Biopharma headquartered?
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.#N#More...
What is CTI Biopharma?
and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington. More...
Is a B better than a C?
is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington.